Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apomorphine pump with or without dopamine agonists in Parkinson's disease
NCT03693872Completed
- Sponsor
- CHU Rennes
- Start
- May 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of apomorphine in Parkinson's disease (PD), sponsored by CHU Rennes. Primary endpoint: Non Motor Symptoms Scale at 6 months. Started May 2019; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03693872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693872.